Uncomplicated Urinary Tract Infection Treatment Market is expected to grow with a 10% CAGR during 2023 to 2033

During the forecast period 2023 to 2033, the Uncomplicated Urinary Tract Infection Treatment market demand is expected to grow at a value of 10% CAGR, according to Future Market Insights. By the year 2033, the global market for Uncomplicated Urinary Tract Infection Treatment is expected to rise to a market valuation of US$ 17 Billion. Growth of the market can be attributed to increasing awareness of the condition, the growing geriatric population, and the rising incidence of UTIs.

One of the key drivers of the market is the increasing awareness of UTIs. With the growing availability of information online and through social media, more and more people are becoming aware of the symptoms of UTIs and the importance of seeking prompt treatment. This is leading to higher demand for antibiotics and other treatments, driving growth in the market.

Get Sample Report + Related Graphs & Charts@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16923

Another factor driving the market is the growing geriatric population. As people age, their risk of developing UTIs increases, and with the world’s population aging rapidly, the demand for UTI treatments is also increasing. According to the United Nations, the number of people aged 65 and over is expected to triple by 2050, reaching nearly 1.5 billion.

Finally, the rising incidence of UTIs is also contributing to the growth of the market. Factors such as the growing prevalence of diabetes, changes in sexual behavior, and the increasing use of catheters and other medical devices are all leading to higher rates of UTIs. This is creating a growing demand for effective treatments that can quickly and safely clear up UTIs.

Key Takeaways from the Market Study

• The global Uncomplicated Urinary Tract Infection Treatment market is expected to grow with a 10% CAGR during 2023 to 2033.
• Retail pharmacies are expected to hold 47% of the market share in 2023 for Uncomplicated Urinary Tract Infection Treatment market.
• North America is expected to possess 48% market share for Uncomplicated Urinary Tract Infection Treatment market in 2023.
• Europe Uncomplicated Urinary Tract Infection Treatment market size is expected to possess 40% market share in 2023.
• Retail Pharmacies Expected to Procure 47% Market Share for Uncomplicated Urinary Tract Infection Treatment Market: FMI Study

“Key players are investing heavily in research and development to bring new and improved treatments to market, and are also working to expand their distribution networks to reach more patients.” states an FMI analyst

To remain ‘ahead’ of your competitors, Ask a Question@ https://www.futuremarketinsights.com/ask-question/rep-gb-16923

Competitive Landscape

Key players in the Uncomplicated Urinary Tract Infection Treatment market are GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, Pfizer, Allergan Plc, Bristol-Myers Squibb, Merck & Co., Inc., Cipla Inc.

• GSK has developed a drug called Avycaz, which is a combination of ceftazidime and avibactam, used for the treatment of complicated UTIs. Avycaz is effective against a wide range of gram-negative bacteria, including some that are resistant to other antibiotics.
• Iterum Therapeutics is a biopharmaceutical company that is focusing on developing novel antibiotics to treat infections caused by multi-drug resistant pathogens, including those that cause Uncomplicated Urinary Tract Infections (UTIs).

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Uncomplicated Urinary Tract Infection Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights based on Drug Class (Gepotidacin, Probenecid, Sulfonamide, Tetracycline, Nitrofuran) Distribution Channel (Hospital Pharmacies, Gynaecology and Urology Clinics, Retail Pharmacies, Online Drug Stores) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)

For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/16923

Key Segments Profiled in the Uncomplicated Urinary Tract Infection Treatment Industry Survey

Drug Class:

• Gepotidacin
• Probenecid
• Sulfonamide
• Tetracycline
• Nitrofuran

Distribution Channel:

• Hospital Pharmacies
• Gynaecology and Urology Clinics
• Retail Pharmacies
• Online Drug Stores

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs